Molecular body imaging: MR imaging, CT, and US. Part I. Principles

Radiology

Volumn 263, Issue 3, 2012, Pages 633-643

  Kircher, Moritz F ^a   Willmann, Jürgen K ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CHEMICAL EXCHANGE SATURATION TRANSFER AGENT; CROSS LINKED IRON OXIDE; FLUORINE; MONODISPERSE IRON OXIDE NANOPARTICLE; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; ECHOGRAPHY; ENZYME ACTIVITY; FLUORINE NUCLEAR MAGNETIC RESONANCE; HUMAN; HYPERPOLARIZATION; IMAGE DISPLAY; IMAGE ENHANCEMENT; IMAGE QUALITY; MICROBUBBLE; MOLECULAR IMAGING; MOLECULAR PROBE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REVIEW; SENSITIVITY AND SPECIFICITY; STRUCTURE ACTIVITY RELATION;

CONTRAST MEDIA; HUMANS; LIPOSOMES; MAGNETIC RESONANCE IMAGING; MICROBUBBLES; MOLECULAR IMAGING; NANOPARTICLES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 84862494494     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12102394     Document Type: Review

References (87)

1. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 2008;452(7187):580-589. (Pubitemid 351483372)
2. Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H. MRI of the prostate: clinical relevance and emerging applications. J Magn Reson Imaging 2011;33(2):258-274.
3. Vargas HA, Akin O, Franiel T, et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 2011;259(3):775-784.
4. Biswal S, Resnick DL, Hoffman JM, Gambhir SS. Molecular imaging: integration of molecular imaging into the musculoskeletal imaging practice. Radiology 2007;244(3):651-671. (Pubitemid 47292078)
5. Pysz MA, Willmann JK. Targeted contrast-enhanced ultrasound: an emerging technology in abdominal and pelvic imaging. Gastroenterology 2011;140(3):785-790.
6. Kircher MF, Gambhir SS, Grimm J. Noninvasive cell-tracking methods. Nat Rev Clin Oncol 2011;8(11):677-688.
7. Pysz MA, Gambhir SS, Willmann JK. Molecular imaging: current status and emerging strategies. Clin Radiol 2010;65(7):500-516.
8. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov 2008;7(7):591-607. (Pubitemid 351927724)
9. Zavaleta CL, Kircher MF, Gambhir SS. Raman's "effect" on molecular imaging. J Nucl Med 2011;52(12):1839-1844.
10. Islam T, Josephson L. Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nanoparticles. Cancer Biomark 2009;5(2):99-107.
11. Chen JW, Querol Sans M, Bogdanov A Jr, Weissleder R. Imaging of myeloperoxidase in mice by using novel amplifiable paramagnetic substrates. Radiology 2006;240(2):473-481. (Pubitemid 44098644)
12. Louie AY, Hüber MM, Ahrens ET, et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000;18(3):321-325. (Pubitemid 30159486)
13. Nahrendorf M, Sosnovik D, Chen JW, et al. Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation 2008;117(9):1153-1160. (Pubitemid 351552019)
14. Ronald JA, Chen JW, Chen Y, et al. Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation 2009;120(7):592-599.
15. Elias DR, Thorek DL, Chen AK, Czupryna J, Tsourkas A. In vivo imaging of cancer biomarkers using activatable molecular probes. Cancer Biomark 2008;4(6):287-305.
16. Buchner AM, Shahid MW, Heckman MG, et al. Comparison of probe-based confocal laser endomicroscopy with virtual chromoendoscopy for classification of colon polyps. Gastroenterology 2010;138(3):834-842.
17. Wolfsen HC. New technologies for imaging of Barrett's esophagus. Surg Oncol Clin N Am 2009;18(3):487-502.
18. Gibbs-Strauss SL, Rosenberg M, Clough BL, Troyan SL, Frangioni JV. First-in-human clinical trials of imaging devices: an example from optical imaging. Conf Proc IEEE Eng Med Biol Soc 2009;2009:2001-2004.
19. Matsui A, Tanaka E, Choi HS, et al. Real-time intra-operative near-infrared fluorescence identification of the extrahepatic bile ducts using clinically available contrast agents. Surgery 2010;148(1):87-95.
20. Troyan SL, Kianzad V, Gibbs-Strauss SL, et al. The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol 2009;16(10):2943-2952.
21. Willmann JK, Lutz AM, Paulmurugan R, et al. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology 2008;248(3):936-944.
22. De la Zerda A, Zavaleta C, Keren S, et al. Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol 2008;3(9):557-562.
23. Kircher MF, De la Zerda A, Jokerst J, et al. A brain tumor molecular imaging strategy using a novel triple-modality nanoparticle. Nat Med (in press).
24. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003;17(5):545-580. (Pubitemid 36307540)
25. Frangioni JV, Hajjar RJ. In vivo tracking of stem cells for clinical trials in cardiovascular disease. Circulation 2004;110(21): 3378-3383. (Pubitemid 39557503)
26. Klibanov AL, Rasche PT, Hughes MS, et al. Detection of individual microbubbles of ultrasound contrast agents: imaging of free-floating and targeted bubbles. Invest Radiol 2004;39(3):187-195. (Pubitemid 38263925)
27. Aime S, Cabella C, Colombatto S, Geninatti Crich S, Gianolio E, Maggioni F. Insights into the use of paramagnetic Gd(III) complexes in MR-molecular imaging investigations. J Magn Reson Imaging 2002;16(4):394-406. (Pubitemid 35167875)
28. Sosnovik DE, Nahrendorf M, Weissleder R. Molecular magnetic resonance imaging in cardiovascular medicine. Circulation 2007;115(15):2076-2086. (Pubitemid 46625959)
29. Shen T, Weissleder R, Papisov M, Bogdanov A Jr, Brady TJ. Monocrystalline iron oxide nanocompounds (MION): physicochemical properties. Magn Reson Med 1993;29(5):599-604. (Pubitemid 23138048)
30. Wunderbaldinger P, Josephson L, Weissleder R. Crosslinked iron oxides (CLIO): a new platform for the development of targeted MR contrast agents. Acad Radiol 2002;9(Suppl 2):S304-S306. (Pubitemid 34857701)
31. Kircher MF, Josephson L, Weissleder R. Ratio imaging of enzyme activity using dual wavelength optical reporters. Mol Imaging 2002;1(2):89-95.
32. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 2003;63(23):8122-8125. (Pubitemid 37549457)
33. Kircher MF, Weissleder R, Josephson L. A dual fluorochrome probe for imaging proteases. Bioconjug Chem 2004;15(2):242-248. (Pubitemid 38365183)
34. Kircher MF, Allport JR, Graves EE, et al. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res 2003;63(20):6838-6846. (Pubitemid 37322966)
35. Zhao M, Kircher MF, Josephson L, Weissleder R. Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjug Chem 2002;13(4):840-844. (Pubitemid 34801127)
36. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348(25):2491-2499. (Pubitemid 36706536)
37. Högemann-Savellano D, Bos E, Blondet C, et al. The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia 2003;5(6):495-506. (Pubitemid 38045087)
38. Swanson SD, Kukowska-Latallo JF, Patri AK, et al. Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement. Int J Nanomedicine 2008;3(2):201-210. (Pubitemid 352037852)
39. Mulder WJ, Strijkers GJ, van Tilborg GA, Griffioen AW, Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed 2006;19(1):142-164. (Pubitemid 43250800)
40. Ghaghada KB, Ravoori M, Sabapathy D, Bankson J, Kundra V, Annapragada A. New dual mode gadolinium nanoparticle contrast agent for magnetic resonance imaging. PLoS ONE 2009;4(10):e7628.
41. Morawski AM, Winter PM, Crowder KC, et al. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med 2004;51(3):480-486. (Pubitemid 38298660)
42. Skajaa T, Cormode DP, Falk E, Mulder WJ, Fisher EA, Fayad ZA. High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler Thromb Vasc Biol 2010;30(2):169-176.
43. Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol 2005;23(8):983-987. (Pubitemid 41114032)
44. Kadayakkara DK, Janjic JM, Pusateri LK, Young WB, Ahrens ET. In vivo observation of intracellular oximetry in perfluorocarbon-labeled glioma cells and chemotherapeutic response in the CNS using fluorine-19 MRI. Magn Reson Med 2010;64(5):1252-1259.
45. Hancu I, Dixon WT, Woods M, Vinogradov E, Sherry AD, Lenkinski RE. CEST and PARACEST MR contrast agents. Acta Radiol 2010;51(8):910-923.
46. Ward KM, Aletras AH, Balaban RS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J Magn Reson 2000;143(1):79-87.
47. Woods M, Woessner DE, Sherry AD. Paramagnetic lanthanide complexes as PARACEST agents for medical imaging. Chem Soc Rev 2006;35(6):500-511. (Pubitemid 43815284)
48. Zhang S, Merritt M, Woessner DE, Lenkinski RE, Sherry AD. PARACEST agents: modulating MRI contrast via water proton exchange. Acc Chem Res 2003;36(10):783-790.
49. Aime S, Carrera C, Delli Castelli D, Geninatti Crich S, Terreno E. Tunable imaging of cells labeled with MRI-PARACEST agents. Angew Chem Int Ed Engl 2005;44(12):1813-1815.
50. Aime S, Delli Castelli D, Lawson D, Terreno E. Gd-loaded liposomes as T1, susceptibility, and CEST agents, all in one. J Am Chem Soc 2007;129(9):2430- 2431. (Pubitemid 46364037)
51. Aime S, Delli Castelli D, Terreno E. Highly sensitive MRI chemical exchange saturation transfer agents using liposomes. Angew Chem Int Ed Engl 2005;44(34):5513-5515. (Pubitemid 41273307)
52. Delli Castelli D, Dastrù W, Terreno E, et al. In vivo MRI multicontrast kinetic analysis of the uptake and intracellular trafficking of paramagnetically labeled liposomes. J Control Release 2010;144(3):271-279.
53. Querol M, Bogdanov A Jr. Environment-sensitive and enzyme-sensitive MR contrast agents. Handb Exp Pharmacol 2008;(185 Pt 2):37-57.
54. Bogdanov A Jr, Matuszewski L, Bremer C, Petrovsky A, Weissleder R. Oligomerization of paramagnetic substrates result in signal amplification and can be used for MR imaging of molecular targets. Mol Imaging 2002;1(1):16-23.
55. Rodríguez E, Nilges M, Weissleder R, Chen JW. Activatable magnetic resonance imaging agents for myeloperoxidase sensing: mechanism of activation, stability, and toxicity. J Am Chem Soc 2010;132(1):168-177.
56. Perez JM, Josephson L, O'Loughlin T, Högemann D, Weissleder R. Magnetic relaxation switches capable of sensing molecular interactions. Nat Biotechnol 2002;20(8):816-820. (Pubitemid 34836759)
57. Perez JM, Simeone FJ, Saeki Y, Josephson L, Weissleder R. Viral-induced self-assembly of magnetic nanoparticles allows the detection of viral particles in biological media. J Am Chem Soc 2003;125(34):10192-10193. (Pubitemid 37022228)
58. Grimm J, Perez JM, Josephson L, Weissleder R. Novel nanosensors for rapid analysis of telomerase activity. Cancer Res 2004;64(2):639-643. (Pubitemid 38120904)
59. Perez JM, Grimm J, Josephson L, Weissleder R. Integrated nanosensors to determine levels and functional activity of human telomerase. Neoplasia 2008;10(10):1066-1072.
60. Yoo B, Pagel MDA. A PARACEST MRI contrast agent to detect enzyme activity. J Am Chem Soc 2006;128(43):14032-14033. (Pubitemid 44657488)
61. Chauvin T, Durand P, Bernier M, et al. Detection of enzymatic activity by PARACEST MRI: a general approach to target a large variety of enzymes. Angew Chem Int Ed Engl 2008;47(23):4370-4372.
62. Josephson L, Kircher MF, Mahmood U, Tang Y, Weissleder R. Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjug Chem 2002;13(3):554-560. (Pubitemid 34527517)
63. Golman K, Olsson LE, Axelsson O, Månsson S, Karlsson M, Petersson JS. Molecular imaging using hyperpolarized 13C. Br J Radiol 2003;76(Spec No 2):S118-S127. (Pubitemid 39530305)
64. Kurhanewicz J, Vigneron DB, Brindle K, et al. Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia 2011;13(2):81-97.
65. Viale A, Aime S. Current concepts on hyperpolarized molecules in MRI. Curr Opin Chem Biol 2010;14(1):90-96.
66. Golman K, Petersson JS, Ardenkjaer-Larsen JH, et al. Dynamic in vivo oxymetry using overhauser enhanced MR imaging. J Magn Reson Imaging 2000;12(6):929-938.
67. Middleton H, Black RD, Saam B, et al. MR imaging with hyperpolarized 3He gas. Magn Reson Med 1995;33(2):271-275.
68. Albert MS, Cates GD, Driehuys B, et al. Biological magnetic resonance imaging using laser-polarized 129Xe. Nature 1994;370(6486):199-201.
69. Golman K, Axelsson O, Jóhannesson H, Månsson S, Olofsson C, Petersson JS. Parahydrogen-induced polarization in imaging: subsecond (13)C angiography. Magn Reson Med 2001;46(1):1-5. (Pubitemid 32592131)
70. Ardenkjaer-Larsen JH, Fridlund B, Gram A, et al. Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. Proc Natl Acad Sci USA 2003;100(18):10158-10163. (Pubitemid 37071849)
71. de Vries A, Custers E, Lub J, van den Bosch S, Nicolay K, Grüll H. Block-copolymer-stabilized iodinated emulsions for use as CT contrast agents. Biomaterials 2010;31(25):6537-6544.
72. Hyafil F, Cornily JC, Feig JE, et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 2007;13(5):636-641. (Pubitemid 46828482)
73. Kong WH, Lee WJ, Cui ZY, et al. Nanoparticulate carrier containing water-insoluble iodinated oil as a multifunctional contrast agent for computed tomography imaging. Biomaterials 2007;28(36):5555-5561.
74. Elrod DB, Partha R, Danila D, Casscells SW, Conyers JL. An iodinated liposomal computed tomographic contrast agent prepared from a diiodophosphatidylcholine lipid. Nano medicine 2009;5(1):42-45.
75. Aviv H, Bartling S, Kieslling F, Margel S. Radiopaque iodinated copolymeric nanoparticles for x-ray imaging applications. Biomaterials 2009;30(29):5610-5616.
76. Galperin A, Margel D, Baniel J, Dank G, Biton H, Margel S. Radiopaque iodinated polymeric nanoparticles for x-ray imaging applications. Biomaterials 2007;28(30):4461-4468. (Pubitemid 47212418)
77. Rabin O, Manuel Perez J, Grimm J, Wojtkiewicz G, Weissleder R. An x-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater 2006;5(2):118-122. (Pubitemid 43177900)
78. Deshpande N, Needles A, Willmann JK. Molecular ultrasound imaging: current status and future directions. Clin Radiol 2010;65(7):567-581.
79. Hwang M, Lyshchik A, Fleischer AC. Molecular sonography with targeted microbubbles: current investigations and potential applications. Ultrasound Q 2010;26(2):75-82.
80. Kiessling F, Huppert J, Palmowski M. Functional and molecular ultrasound imaging: concepts and contrast agents. Curr Med Chem 2009;16(5):627-642.
81. Deshpande N, Pysz MA, Willmann JK. Molecular ultrasound assessment of tumor angiogenesis. Angiogenesis 2010;13(2):175-188.
82. Cheng KT. Sonicated human serum microspheres. Molecular Imaging and Contrast Agent Database. Bethesda, Md: MICAD, 2004.
83. Klibanov AL. Molecular imaging with targeted ultrasound contrast microbubbles. Ernst Schering Res Found Workshop 2005 (49):171-191.
84. Walday P, Tolleshaug H, Gjøen T, et al. Biodistributions of air-filled albumin microspheres in rats and pigs. Biochem J 1994;299(Pt 2):437-443. (Pubitemid 24114137)
85. Deshpande N, Willmann JK. Microparticle- and nanoparticle-based contrast-enhanced ultrasound imaging. In: Chen X, ed. Nanoplatform-based molecular imaging. Hoboken, NJ: Wiley, 2011. doi:10.1002/9780470767047.ch11.
86. de Jong N, Hoff L. Ultrasound scattering properties of Albunex microspheres. Ultrasonics 1993;31(3):175-181.
87. Arditi M, Frinking PJ, Zhou X, Rognin NG. A new formalism for the quantification of tissue perfusion by the destruction replenishment method in contrast ultrasound imaging. IEEE Trans Ultrason Ferroelectr Freq Control 2006;53(6):1118-1129. (Pubitemid 46405092)